Trial description:
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA)
Contact name:
Dr Danish Mazhar
Trial start date:
Tuesday, September 24, 2019
Trial end date:
Wednesday, December 30, 2020
Trial tumour type:
Prostate
Show on Radiotherapy:
No
